Opinion: The Best Projects Are Least Obvious

Today’s technologies have opened all sorts of experimental avenues. Deciding which questions are best to pursue requires a certain degree of restraint.

Written byNikolai Slavov
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

FLICKR, T_BUCHTELEWe are fortunate to live in an exciting time. Today, new technologies enable the design and execution of straightforward experiments, many of which were not possible just a few years ago. These experiments hold the potential to bring new discoveries and to improve medical care. An abundance of obvious-next-step experiments creates a buzz of activities and excitement that is quite palpable among graduate students, postdocs, and professors alike.

Such enthusiasm permeates the air and stimulates; it also overwhelms. It seems there is always so much to do and never enough time to do it. Recent findings have opened up many new research avenues, and emerging technologies are ever-alluring. How are investigators to pursue all of these things, given our limited time? Or, failing that, how can we at least choose the best leads to follow?

Much of the aforementioned buzz is often the result of an overabundance of next-step projects that are obvious to most researchers. Many of these projects are quite good, but rarely are they exceptional—at least in the sense that they result in a nontrivial connection. It’s not often that these projects help researchers advance their fields. Many such projects ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies